Bart De Strooper, MD, PhD, UK Dementia Research Institute and University College London, London, UK, discusses therapeutic targets for Alzheimer’s disease and the lack of funding. Currently, there are drugs targeted at amyloid and tau to lower the protein load, however, this is not enough. They are tested in patients with late-stage disease, in which it is too late to prevent dementia. Furthermore, the Alzheimer’s field is severely underfunded. An increase in funds could help deepen our understanding of the disease and develop new therapies. This interview took place during the Virtual World Congress on Controversies in Neurology (CONy) 2020.
Consultant for EISAI and Janssen Pharmaceutics. Research funding from Janssen Pharmaceutics.